FDA Chief Defends Replimune Rejection, Cites Independent Reviews and Precedents
TL;DR Summary
FDA Commissioner Marty Makary defended the agency’s rejection of Replimune’s melanoma drug candidate in a CNBC interview, saying independent review teams reached the same conclusion and denying corrupt sweetheart deals, while pointing to past approvals like Aduhelm and a Covid-19 booster for young healthy kids as precedents.
- FDA commissioner defends agency's drug approval decisions after wave of backlash CNBC
- Why the FDA rejected a ‘breakthrough’ melanoma drug Scientific American
- Opinion | Replimune’s Fate Is Worse Than a Tragedy WSJ
- FDA Commissioner Makary Defends Agency's Decision on Replimune's Drug U.S. News & World Report
- Fda's Makary on Replimune Says Three Indepndent Teams Arrived at the Same Conclusions - Cnbc marketscreener.com
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
1 min
vs 2 min read
Condensed
85%
309 → 47 words
Want the full story? Read the original article
Read on CNBC